FBIO News - Candlesense

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:FBIO) MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to en...

Investor

13 days ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value ri...

How might the broader market sentiment toward biotech M&A and the 70 sentiment score influence short‑term trading activity in FBIO? Will the acquisition create any dilution for existing shareholders, and how will that be reflected in the share count and earnings per share? What risks are associated with the regulatory approval and commercialization of UNLOXCYT™ that could affect the royalty stream?

Mergers

about 1 month ago